A Phase 1 study of CM 536
Latest Information Update: 03 Dec 2025
At a glance
- Drugs CM 536 (Primary)
- Indications Inflammation
- Focus Adverse reactions
Most Recent Events
- 03 Dec 2025 New trial record
- 10 Nov 2025 According to the Belenos Biosciences media release, company initiating Phase 1 study in 1Q2026.